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Inﬂammatory myoﬁbroblastic tumor (IMT) is a rare neoplasm that occurs at diﬀerent sites in the 
body.  Pleural IMT in particular is especially rare.  IMTs infrequently tend to have malignancy.  We 
report a rare case of advanced diaphragmatic parietal pleural IMT with dissemination.  A 30-year-old 
woman complained of right upper abdominal pain.  Computed tomography showed a large lobulated 
mass over the right diaphragm, but no disseminated nodules were noted.  Intraoperatively,  we found 
the primary tumor arising from the diaphragmatic parietal pleura and a dozen disseminated nodules,  
and we removed them completely.  The histopathological and immunohistochemical diagnosis was 
IMT.
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nﬂammatory myoﬁbroblastic tumor (IMT) is a 
rare neoplasm that has been reported to occur 
in nearly every site in the body,  including the lung,  
bladder,  spleen,  breast,  pancreas,  liver,  colon,  
prostate,  peripheral nerves,  soft tissue and orbit.  In 
the chest site,  IMT commonly arises in the lung nod-
ules.  Pulmonary IMTs were reported to occupy 
0.04ｵ of resected lung nodules [1,  2].  A pleural 
IMT of the diaphragm or chest wall is a rare clinical 
entity compared to pulmonary IMT [3-5].  IMT has 
been considered a primary immunologic lesion,  ﬁbro-
genetic disorder,  or a speciﬁc reaction to infectious 
agents,  trauma,  or adjacent necrosis or neoplasm [2].  
Chromosomal translocation involving the anaplastic 
lymphoma kinase (ALK) gene was present in 50ｵ of 
IMTs,  and approximately half of IMTs may be malig-
nant [6].  Histologically,  IMT belongs to a subgroup 
in the broad category of inﬂammatory pseudotumors 
and consists of a variable mixture of collagen,  inﬂam-
matory cells and usually cytologically bland spindle 
cells showing myoﬁbroblastic diﬀerentiation [7].  IMT 
is an intermediate malignant soft tissue tumor because 
it can be infrequently confused with a malignant tumor 
to invasive locally,  recur or metastasize [3][8].  
Here we report a rare case of advanced diaphragmatic 
parietal pleural IMT with dissemination.
Case Report
　 A 30-year-old woman complained of right upper 
abdominal pain and sought medical attention at a 
nearby outpatient clinic.  Chest X-ray showed blunting 
of the right costophrenic angle,  and abdominal com-
puted tomography (CT) revealed a 7.8cm well-deﬁned 
low attenuation lesion over the right diaphragm.  She 
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was subsequently referred to our hospital.   
　 Her past history included appendectomy at the age 
of 14.  Her family history was unremarkable.  She had 
been smoking half a pack of cigarettes per day for 14 
years upon visiting our hospital.  
　 She had experienced pain in the right upper abdo-
men when coughing over the last few months.  No 
other abnormalities were observed on a chest and 
abdominal physical examination.  Her complete blood 
count was within the normal range.  Her levels of 
blood urea nitrogen,  creatinine,  liver function,  
C-reactive protein (CRP) and electrolytes were within 
normal limits.
　 Contrast-enhanced CT showed a 7.8×3cm hetero-
geneous lobulated mass over the right diaphragm with 
early phase heterogeneous and delayed enhancement 
(Fig.  1).  Very slight pleural eﬀusion but no dissemi-
nated nodules were noted.  The maximum standardized 
uptake value on ﬂuorodeoxyglucose positron emission 
tomography in the tumor lesion was 2.6.  In the tumor,  
T1-weighted magnetic resonance imaging (MRI) 
showed isointense lesions,  and T2-weighted MRI 
showed mixed isointense and mild hypointense lesions.  
We preoperatively diagnosed solitary ﬁbrous tumor 
(SFT) arising from the pleura of the diaphragm or 
chest wall.
　 The patient underwent video-assisted thoracic 
surgery for the purpose of diagnosis and treatment.  
Intraoperatively,  the primary tumor,  with a stalk,  
was seen arising from the diaphragmatic parietal 
pleura and was ﬂexible on the diaphragm without inva-
sion.  A dozen disseminated 3-15mm nodules were 
found nearby on the parietal pleura of the chest wall 
and diaphragm,  but no pleural eﬀusion was observed 
(Fig.  2).  The primary tumor and all visible dissemi-
nated nodules were completely removed.
　 The histological ﬁndings on hematoxylin and eosin 
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Fig. 1　 Contrast-enhanced computed tomography showed a 
7.8×3cm heterogeneous lobulated mass over the right diaphragm. 
It showed early phase heterogeneous and delayed enhancement.
Fig. 2　 The primary tumor arose from the diaphragmatic parietal pleura with a stalk (white arrow). Then, a dozen disseminated 3-15mm 
nodules were found on nearby parietal pleura on the chest wall and diaphragm.
staining suggested proliferation of spindle cells (ﬁbro-
blasts and myoﬁbroblasts) and round cells (macro-
phages,  lymphocytes and plasma cells) (Fig.  3).  
However,  no evidence of malignancy,  nuclear pleo-
morphism,  or necrosis was found.  Occasional mitoses,  
with 2mitoses/50high-power ﬁelds,  were observed.  
In immunohistochemistry,  the tumor was negative for 
cytokeratin AE1/3,  CD117,  smooth muscle cell actin 
(SMA) and S100.  It was positive for calponin and 
HHF-35,  and slight staining for desmin and CD34 
was seen.  The percentage of MIB-1 staining in the 
tumor was less than 1ｵ,  indicating low proliferative 
capacity.  ALK was negative.  There were no signs of 
a speciﬁc infectious disease such as tuberculosis.  We 
ﬁnally diagnosed IMT after the histopathological and 
immunohistochemical analyses.  The primary tumor 
arising from the diaphragmatic parietal pleura and the 
disseminated nodules showed the same pathological 
results.
　 We did not perform adjuvant chemotherapy or 
radiotherapy.  The patient has remained asymptomatic 
and free from recurrence for 1 year after the opera-
tion.
Discussion
　 Previous studies have reported that most IMTs 
manifest as solitary masses in the lung parenchyma 
[1,  2].  In the chest,  IMTs arising from extrapulmo-
nary sites such as the pleura,  diaphragm and chest 
wall are rare and have appeared in only a few reports 
[3-5].  IMT can occur commonly in patients under 40 
years of age,  and our patient was young,  at age 30 
[2].  The ﬁndings of clinical examination and labora-
tory tests tend to be nonspeciﬁc or unremarkable [5].  
The nonspeciﬁc imaging characteristics of IMT make 
it diﬃcult to reach a preoperative diagnosis [9,  10].  
We made a preoperative diagnosis of SFT based on 
the imaging ﬁndings and the frequency of occurrence 
in the chest wall or in pleural tumors.
　 Histologically,  IMT is a distinctive neoplasm 
characterized by the presence of myoﬁbroblasts and 
chronic inﬂammatory cells; the histopathological ﬁnd-
ings in this case were consistent with IMT [7].  In 
immunohistochemistry,  positive results for SMA 
(86ｵ) were frequently seen in a previous report 
[11].  The tumor was negative for SMA in the present 
case,  but it was positive for calponin,  HHF-35 and 
desmin,  which were myoﬁbroblast markers same as 
SMA.  According to these results and other negative 
stains such as cytokeratin AE1/3,  CD117 and S100,  
the pathological diagnosis was IMT.  
　 Most IMTs manifest as solitary masses with dis-
crete margins and have good prognoses if completely 
resected,  because recurrence after complete resection 
is rare [3].  However,  patients with incompletely 
resected or recurrent IMTs have been reported to 
have poor prognoses,  because no eﬀective treatment 
for this disease has been established [3].  In this case,  
the primary tumor and all visible disseminated nodules 
were completely removed,  but visually unidentiﬁed 
disseminated nodules might have been missed.  We did 
not perform adjuvant chemotherapy or radiotherapy 
because they have not been established as eﬃcient 
treatments for IMT [5].  Anticancer drug combina-
tions of paclitaxel and carboplatin or celecoxib and 
methotrexate have been reported to be helpful for 
advanced IMTs that are unresectable,  show invasive-
ness,  or have metastasized [12,  13].  It has been 
reported that non-steroidal anti-inﬂammatory drugs and 
steroids are also therapeutic [14].  Crizotinib,  an 
ALK inhibitor,  has been eﬀective in some cases where 
ALK is positive on immunohistochemistry [15].  
However,  the results of these treatments have been 
widely variable,  ranging from ineﬀective to complete 
regression.  
　 We reported here a rare case of advanced dia-
phragmatic parietal pleural IMT with dissemination.  
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Fig. 3　 The hematoxylin and eosin histology suggested the prolif-
eration of spindle cells (ﬁbroblasts and myoﬁbroblasts) and mono-
morphic cells (macrophages, lymphocytes and plasma cells).
The patient has remained asymptomatic and free from 
recurrence for one year after resection,  but careful 
observation is required.
References
 1.  Coﬃn CM,  Watterson J,  Priest JR and Dehner LP: Extrapulmonary 
inﬂammatory myoﬁbroblastic tumor (inﬂammatory pseudotumor).  A 
clinicopathologic and immunohistochemical study of 84 cases.  Am 
J Surg Pathol (1995) 19: 859-872.
 2.  Cerfolio RJ,  Allen MS,  Nascimento AG,  Deschamps C,  
Trastek VF,  Miller DL and Pairolero PC: Inﬂammatory pseudotu-
mors of the lung.  Ann Thorac Surg (1999) 67: 933-936.
 3.  Lee HJ,  Kim JS,  Choi YS,  Kim K,  Shim YM,  Han J and Kim J:  
Treatment of inﬂammatory myoﬁbroblastic tumor of the chest: the 
extent of resection. Ann Thorac Surg (2007) 84: 221-224.
 4.  Bothale KA,  Mahore SD,  Patrikar AD and Mitra K: A rare case of 
inﬂammatory myoﬁbroblastoma of diaphragm.  Indian J Surg (2013) 
75: 243-246.
 5.  Loeﬄer-Ragg J,  Bodner J,  Freund M,  Steurer M,  Uprimny C,  
Zelger B and Kahler CM: Diagnostic and therapeutic challenges of 
a large pleural inﬂammatory myoﬁbroblastic tumor.  Case Rep 
Pulmonol (2012) 2012: 102196.
 6.  Li J,  Yin WH,  Takeuchi K,  Guan H,  Huang YH and 
Chan JK: Inﬂammatory myoﬁbroblastic tumor with RANBP2 and 
ALK gene rearrangement: a report of two cases and literature 
review.  Diagn Pathol (2013) 8: 147.
 7.  Pettinato G,  Manivel JC,  De Rosa N and Dehner LP: Inﬂammatory 
myoﬁbroblastic tumor (plasma cell granuloma).  Clinicopathologic 
study of 20 cases with immunohistochemical and ultrastructural 
observations.  Am J Clin Pathol (1990) 94: 538-546.
 8.  Jo VY,  Fletcher CD: WHO classiﬁcation of soft tissue tumours: an 
update based on the 2013 (4th) edition.  Pathology (2014) 46: 95-
104.
 9.  Kakitsubata Y,  Theodorou SJ,  Theodorou DJ,  Nabeshima K,  
Kakitsubata S and Friedman PJ: Myoﬁbroblastic inﬂammatory 
tumor of the lung: CT ﬁndings with pathologic correlation.  Comput 
Med Imaging Graph (2007) 31: 607-613.
10.  Takayama Y,  Yabuuchi H,  Matsuo Y,  Soeda H,  Okafuji T,  
Kamitani T,  Kinoshita Y,  Kubokura N,  Sakai S,  Oda Y,  
Hatakenaka M and Honda H: Computed tomographic and mag-
netic resonance features of inﬂammatory myoﬁbroblastic tumor of 
the lung in children.  Radiat Med (2008) 26: 613-617.
11.  Makhlouf HR and Sobin LH: Inﬂammatory myoﬁbroblastic tumors 
(inﬂammatory pseudotumors) of the gastrointestinal tract: how 
closely are they related to inﬂammatory ﬁbroid polyps? Hum Pathol 
(2002) 33: 307-315.
12.  Kubo N,  Harada T,  Anai S,  Otsubo K,  Yoneshima Y,  Ijichi K,  
Koga T,  Takayama K and Nakanishi Y: Carboplatin plus paclitaxel 
in the successful treatment of advanced inﬂammatory myoﬁbroblas-
tic tumor.  Intern Med (2012) 51: 2399-2401.
13.  Kusunoki-Nakamoto F,  Matsukawa T,  Tanaka M,  Miyagawa T,  
Yamamoto T,  Shimizu J,  Ikemura M,  Shibahara J and 
Tsuji S: Successful treatment of an unresectable inﬂammatory 
myoﬁbroblastic tumor of the frontal bone using a cyclooxygenase-2 
inhibitor and methotrexate.  Intern Med (2013) 52: 623-628.
14.  Applebaum H,  Kieran MW,  Cripe TP,  Coﬃn CM,  Collins MH,  
Kaipainen A,  Laforme A and Shamberger RC: The rationale for 
nonsteroidal anti-inﬂammatory drug therapy for inﬂammatory myoﬁ-
broblastic tumors: a Childrenｾs Oncology Group study.  J Pediatr 
Surg (2005) 40: 999-1003; discussion 1003.
15.  Butrynski JE,  DｾAdamo DR,  Hornick JL,  Dal Cin P,  
Antonescu CR,  Jhanwar SC,  Ladanyi M,  Capelletti M,  Rodig SJ,  
Ramaiya N,   Kwak EL,  Clark JW,  Wilner KD,  Christensen JG,  
Janne PA,  Maki RG,  Demetri GD and Shapiro GI: Crizotinib in 
ALK-rearranged inﬂammatory myoﬁbroblastic tumor.  N Engl J Med 
(2010) 363: 1727-1733.
68 Acta Med.  Okayama　Vol.  69,  No.  1Ueno et al.
